TOKYO, January 31, 2019 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today the following organizational changes, effective April 1, 2019, and personnel changes, effective March 28 and April 1, 2019.

[Details of Organizational Changes]
Effective April 1, 2019
1. Change of the name of Corporate Social Responsibility Dept.
　Corporate Social Responsibility Dept. will be renamed Sustainability Dept.

<Overview>
The “IBI 21,” a new mid-term business plan announced today, positioned “the creation of shared value” as an important management challenge in addition to the conventional agendas to enhance corporate value through spreading corporate ethics and compliance, respect for human rights and management of the environment and health/safety. It set forth the goal of realizing corporate activities that can meet the demands of society through contributions to healthcare and people’s health. The plan defined Corporate Social Responsibility (CSR) as the foundation for realizing the creation of shared value on a long-term and in a sustainable manner, and added that Chugai would work to strengthen it as a sustainability challenge. Accordingly, to clearly define that CSR Dept. is a department responsible for conducting activities that contribute to the long-term sustainability of the company and society, Chugai has decided to change the name.

2. Reorganization of production engineering functions across the Pharmaceutical Technology Div. and Chugai Pharma Manufacturing Co., Ltd. (CPMC)

• Production Engineering Dept. will be renamed Formulation Development Dept. in the Pharmaceutical Technology Div.
• Production engineering function will be newly established at Ukima Plant, CPMC.

<Overview>
The production engineering functions at the Pharmaceutical Technology Div. will be reorganized. Specifically, the production engineering functions that the Production Engineering Dept. currently has (mainly central functions to oversee equipment and facility engineering functions) will be transferred to CPMC’s Ukima Plant in order to strengthen the engineering function through cooperation with each production site. With this transfer, the name of the Production Engineering Dept. will be changed to Formulation Development Dept., as a department responsible for drug formulation development function.

[Details of Personnel Changes]
Effective March 28, 2019

Directors

• The appointment of William N. Anderson and James H. Sabry as Directors is subject to approval at the 108th Annual General Meeting of Shareholders, which is scheduled to be convened on March 28, 2019.
• Daniel O’Day and Sophie Kornowski-Bonnet are scheduled to retire from Directors as of February 28, 2019.

Audit & Supervisory Board Members

• The appointment of Atsushi Sato and Yuko Maeda as Audit & Supervisory Board Member is subject to approval at the 108th Annual General Meeting of Shareholders, which is scheduled to be convened on March 28, 2019.
• Shunji Yokoyama is scheduled to retire from Audit & Supervisory Board Member (Full-time) as of March 28, 2019.

Effective April 1, 2019

Director

Vice President

• Susumu Kato is scheduled to retire from Senior Vice President as of March 31, 2019.